Squarepoint’s XBiotech XBIT Stock Holding History

Squarepoint’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32.7K	Sell	14,941 -19,816	-57%	-$44.7K	﹤0.01%	4316
2026 Q2	$79.9K	Sell	34,757 -6,457	-16%	-$15.6K	﹤0.01%	4233
2026 Q1	$96.9K	Sell	41,214 -22,790	-36%	-$55.1K	﹤0.01%	4074
2025 Q4	$153K	Buy	64,004 +1,845	+3%	+$4.55K	﹤0.01%	3945
2025 Q3	$165K	Buy	62,159 +22,383	+56%	+$66.3K	﹤0.01%	3997
2025 Q2	$118K	Buy	+39,776	New	+$116K	﹤0.01%	4127
2024 Q1	–	Sell	-18,922	Closed	-$75.7K	–	4686
2023 Q4	$75.7K	Buy	+18,922	New	+$75.4K	﹤0.01%	3796
2022 Q3	–	Sell	-11,189	Closed	-$63K	–	3513
2022 Q2	$63K	Buy	+11,189	New	+$75.3K	﹤0.01%	2687
2020 Q2	–	Sell	-11,415	Closed	-$121K	–	2554
2020 Q1	$121K	Sell	11,415 -25,608	-69%	-$417K	﹤0.01%	1602
2019 Q4	$691K	Buy	37,023 +24,135	+187%	+$311K	﹤0.01%	1568
2019 Q3	$135K	Buy	+12,888	New	+$105K	﹤0.01%	2151

Other funds holding XBIT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Squarepoint's XBIT Position: Q3 2026 in Review

Squarepoint reduced its XBiotech (XBIT) stake by 57% in Q3 2026, selling an estimated $44.7K and leaving 14,941 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4316.

Squarepoint first reported a position in XBIT in Q3 2019 and has held it in 11 quarters since. The position peaked at $691K in Q4 2019. 14 funds tracked by Wall St. Rank hold XBIT as of Q3 2026.

Squarepoint held 14,941 shares of XBiotech worth $32.7K as of Q3 2026.
Squarepoint sold 19,816 XBiotech shares in Q3 2026, an estimated $44.7K.
XBiotech made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4316 holding.
Squarepoint first reported a position in XBiotech in Q3 2019 and has held it in 11 quarters since.
Squarepoint's XBiotech position peaked at $691K in Q4 2019.
14 funds tracked by Wall St. Rank held XBiotech as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.